You just read:

Merck KGaA, Darmstadt, Germany's Phase IIb ADDRESS II Results Confirm Potential of Atacicept as a Candidate Therapy for SLE

News provided by

Merck KGaA, Darmstadt, Germany

Nov 14, 2016, 08:00 ET